CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium
07 Diciembre 2022 - 3:30PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the
field of conditionally activated oncology therapeutics, today
announced that Phase 2 data for CX-2009, a conditionally activated
antibody drug conjugate (ADC) targeting CD166, will be presented at
the San Antonio Breast Cancer Symposium on December 8th. The poster
details the results from patients treated with monotherapy
praluzatamab ravtansine for the treatment of advanced HR+/HER2-
breast cancer and triple negative breast cancer (TNBC).
“We thank our investigators and the patients and families who
contributed to our comprehensive evaluation of praluzatamab
ravtansine in breast cancer. Although we elected previously in 2022
not to advance this program further without a partner, this
research has benefited many patients, provided important insights
into our conditionally activated ADC strategy and informed our next
generation of Probody® therapeutic candidates,” said Sean McCarthy,
D.Phil, CEO and Chairman of CytomX.
Details for the poster presentation are
as follows:Presentation Title: Results from a phase 2
study of praluzatamab ravtansine (CX-2009) in patients with
advanced breast cancer (ABC)Poster: P4-01-15Session and Location:
Poster Session 4 – Hall 1Session Date and Time: December 8, 2022,
7:00 am - 8:15 am CTPresenting Author: Dr. Kathy Miller, Indiana
University Melvin and Bren Simon Comprehensive Cancer Center,
Indianapolis, IN, USA
About CytomX Therapeutics,
Inc.CytomX is a clinical-stage, oncology-focused
biopharmaceutical company dedicated to destroying cancer
differently. By pioneering a novel class of conditionally activated
biologics, powered by its Probody® technology platform, CytomX’s
goal is to transcend the limits of current cancer treatments.
CytomX’s robust and differentiated pipeline comprises seven
therapeutic candidates across multiple treatment modalities
including antibody-drug conjugates (“ADCs”), T-cell engaging
bispecific antibodies (“TCBs”), and immune modulators such as
cytokines and checkpoint inhibitors (“CPIs”). CX-2029 is an
investigational conditionally activated antibody-drug conjugate
(ADC) directed toward CD71, which has demonstrated encouraging
antitumor activity in patients with squamous non-small cell lung
cancer and is being developed in collaboration with AbbVie.
CytomX’s clinical pipeline also includes cancer immunotherapeutic
candidates against validated targets such as the CTLA-4-targeting
Probody therapeutics, BMS-986249 and BMS-986288, partnered with
Bristol Myers Squibb, as well as CX-904, a conditionally activated
T-cell-engaging bispecific antibody targeting the epidermal growth
factor receptor (EGFR) on tumor cells and the CD3 receptor on T
cells, which is partnered with Amgen. In addition, CytomX has a
diverse preclinical portfolio of wholly owned assets including
CX-801, an interferon alpha-2b Probody cytokine that has broad
potential applicability in traditionally immuno-oncology sensitive
as well as insensitive (cold) tumors and CX-2051, a conditionally
activated ADC directed toward EpCAM, with potential applicability
across multiple EpCAM-expressing epithelial cancers. Praluzatamab
ravtansine (CX-2009) is an investigational conditionally activated
ADC directed toward CD166 that has demonstrated single agent
clinical activity in a Phase 2 study for patients with advanced
HR+/HER2-non-amplified breast cancer. Following the Phase 2
results, CytomX decided not to further progress praluzatamab
ravtansine alone and is seeking a partner to further develop the
molecule. CytomX has also established strategic collaborations with
multiple leaders in oncology, including AbbVie, Amgen, Astellas,
Bristol Myers Squibb and Regeneron. For more information about
CytomX and how it is working to make conditionally activated
treatments the new standard-of-care in the fight against cancer,
visit www.cytomx.com and follow us on LinkedIn and Twitter.
Forward-Looking StatementsThis
press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements, including those related to the future
potential of partnerships or collaboration agreements. Accordingly,
you should not rely on any of these forward-looking statements,
including those relating to the potential benefits, safety and
efficacy or progress of CytomX’s or any of its collaborative
partners’ product candidates, including CX-2029, BMS-986249,
BMS-986288, pacmilimab, CX-904, CX-801,CX-2051, and praluzatamab
ravtansine, the potential benefits or applications of CytomX’s
Probody platform technology, CytomX’s ability to develop and
advance product candidates into and successfully complete clinical
trials, including the ongoing and planned clinical trials of
CX-2029, BMS-986249, BMS-986288, pacmilimab, CX-904, and
praluzatamab ravtansine, and the timing of the commencement of
clinical trials, initial and ongoing data availability,
investigational new drug applications and other development
milestones. Risks and uncertainties that contribute to the
uncertain nature of the forward-looking statements include: the
unproven nature of CytomX’s novel Probody Platform technology;
CytomX’s clinical trial product candidates are in the initial
stages of clinical development and its other product candidates are
currently in preclinical development, and the process by which
preclinical and clinical development could potentially lead to an
approved product is long and subject to significant risks and
uncertainties, including the risk that the COVID-19 worldwide
pandemic may continue to negatively impact the business, research
and clinical operations of CytomX or its partners, including the
development of preclinical drug candidates due to delays in and
disruption of research activities and the development of clinical
drug candidates due to delays in or disruption of clinical trials,
including impacts on the enrollment of patients in clinical trials
or other clinical trial disruptions; the possibility that the
results of preclinical research and early clinical trials may not
be predictive of future results; the possibility that CytomX’s
clinical trials will not be successful; the possibility that
current preclinical research may not result in additional product
candidates; CytomX’s dependence on the success of CX-2029,
BMS-986249, BMS-986288, pacmilimab, CX-904, CX-801, and CX-2051;
CytomX’s reliance on third parties for the manufacture of the
Company’s product candidates; and possible regulatory developments
in the United States and foreign countries. Additional
applicable risks and uncertainties include those relating to our
preclinical research and development, clinical development, and
other risks identified under the heading "Risk Factors" included in
CytomX’s Quarterly Report on Form 10-Q filed with
the SEC on November 8, 2022. The forward-looking
statements contained in this press release are based on information
currently available to CytomX and speak only as of the date on
which they are made. CytomX does not undertake and specifically
disclaims any obligation to update any forward-looking statements,
whether as a result of any new information, future events, changed
circumstances or otherwise.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
CytomX Contact:Chris OgdenSVP,
Finance and Accountingcogden@cytomx.com317-767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024